Smallpox and Other Viral Agents

Smallpox (Variola Virus) - Pox On You!

• Agent: Variola virus (dsDNA, Poxviridae). Globally eradicated (1980).
• Transmission: Respiratory droplets, direct contact (lesions/fomites). Highly contagious.
• Incubation: 7-17 days.
• Clinical:
  • Prodrome: High fever, malaise, severe headache/backache.
  • Rash: Macules → papules → vesicles → pustules → scabs.
  • Distribution: Centrifugal (face, extremities > trunk). 📌 "SmallPOX, lesions on the periphery BOX".
  • Lesions: Deep-seated, firm, umbilicated.
• Mortality: Variola major ~30%; V. minor <1%.
• Diagnosis: EM (Guarnieri bodies - intracytoplasmic eosinophilic inclusions), PCR.
• Prevention/Tx: Vaccination (Vaccinia virus); Tecovirimat, Cidofovir.
• BT: Category A agent.

⭐ Smallpox rash is centrifugal, lesions are all in the same stage of development in an affected area.

Viral Hemorrhagic Fevers (VHFs) - Code Red Bleeders

• Key Agents: Filoviruses (Ebola, Marburg), Arenaviruses (Lassa), Bunyaviruses (CCHF, Hantavirus), Flaviviruses (Dengue, Yellow Fever).
• Pathogenesis: RNA viruses. Cause endothelial damage → ↑vascular permeability, coagulopathy, shock.
• Clinical: Abrupt onset: fever, myalgia, headache. Progresses to GI symptoms, rash, bleeding (petechiae to severe hemorrhage), organ failure.
• Transmission:
  • Zoonotic reservoirs (rodents, bats, ticks, mosquitoes).
  • Human-to-human via body fluids (high risk in healthcare).
• Diagnosis: RT-PCR (early), serology (later).
• Management: Supportive care (fluids, electrolytes, vasopressors). Strict barrier nursing.

  ⭐ Ribavirin is useful for Lassa Fever and CCHF.

Other Viral Bioterror Agents - Stealthy Spreaders

• Highly Pathogenic Avian Influenza (HPAI): e.g., H5N1, H7N9.
  • Potential for aerosol spread, high mortality.
  • Risk of genetic reassortment → pandemic strains.
• Arboviruses: e.g., Chikungunya, Rift Valley Fever, Japanese Encephalitis.
  • Vector-borne (mosquitoes, ticks); potential for large outbreaks.
  • Stealthy: difficult early detection, rapid spread.
• Nipah Virus: Zoonotic (bats, pigs); respiratory & neurological disease; high fatality.

⭐ Highly Pathogenic Avian Influenza (HPAI) H5N1 is a concern due to potential for aerosol spread and high mortality.

Lab Diagnosis & Antivirals - Viral Counterstrikes

• Lab Diagnosis (Smallpox):
  • PCR (vesicular fluid, scabs): Rapid, specific; gold standard.
  • Electron Microscopy (EM): Brick-shaped virions, Guarnieri bodies (intracytoplasmic).
  • Viral culture (BSL-4); Serology (retrospective).
• Lab Diagnosis (Other VHFs e.g., Ebola, Lassa):
  • RT-PCR (RNA viruses); ELISA (antigen/antibody).
• Antivirals (Smallpox):
  • Tecovirimat (TPOXX/ST-246): Viral p37 envelope protein inhibitor.

    ⭐ Tecovirimat (TPOXX) is an important antiviral for smallpox.

  • Cidofovir: DNA polymerase inhibitor; nephrotoxic.
  • Brincidofovir: Oral cidofovir prodrug, less nephrotoxic.
• Antivirals (Other VHFs):
  • Ribavirin: For Lassa, CCHF, Hantavirus.
  • Supportive care is primary.

Prevention & Prophylaxis - Viral Shield Up!

• Core Measures: Rapid isolation, contact tracing, strict PPE (N95/PAPR, gowns, gloves, eye protection), environmental decontamination.
• Smallpox:
  • Vaccination: Live Vaccinia Virus (VV). 📌 "Vax to Vanquish Variola!"

    ⭐ Smallpox vaccination uses live vaccinia virus and can be effective even post-exposure (within 3-4 days).

  • PEP: Vaccine within 3-4 days post-exposure. Ring vaccination strategy.
  • Antivirals: Tecovirimat.
• Viral Hemorrhagic Fevers (VHFs):
  • Ebola: rVSV-ZEBOV vaccine (pre/post-exposure). mAbs (Inmazeb, Ebanga).
  • Lassa: Ribavirin PEP (early).
  • Strict barrier nursing, safe burials, vector control.

High‑Yield Points - ⚡ Biggest Takeaways

• Smallpox (Variola): DNA virus, aerosol transmission; centrifugal rash (lesions same stage); Guarnieri bodies.
• Smallpox post-exposure: Vaccinia vaccine within 4 days.
• Viral Hemorrhagic Fevers (VHFs) (e.g., Ebola): RNA viruses causing severe systemic illness.
• VHFs cause increased vascular permeability, leading to hemorrhage and shock; mainstay of treatment is supportive care.
• Ribavirin is effective against Lassa fever, CCHF, and Hantavirus.
• Strict barrier nursing and infection control are crucial for VHF management.